SCHEMBL18725355

SCHEMBL18725355

COC(=O)c1ccc(Cl)c(C)n1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.46
NPC1 O15118 2/20 0.46
RAB9A P51151 2/20 0.46
TP53 P04637 2/20 0.46
CYP1A2 P05177 1/20 0.46
CYP3A4 P08684 1/20 0.46
CYP2C9 P11712 1/20 0.46
CYP2C19 P33261 1/20 0.46
NOTUM Q6P988 3/20 0.45
MAPK1 P28482 2/20 0.44
L3MBTL1 Q9Y468 2/20 0.43
KDM4E B2RXH2 2/20 0.43
MAPT P10636 4/20 0.43
NFKB1 P19838 1/20 0.43
NFKB2 Q00653 1/20 0.43
RELA Q04206 1/20 0.43
ALDH1A1 P00352 3/20 0.42
LMNA P02545 2/20 0.42
HPGD P15428 1/20 0.42
HSD17B10 Q99714 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30405765 0.83 NOTUM (0.46) SMN1; SMN2NPC1RAB9ATP53CYP1A2
SCHEMBL17144343 0.83 NOTUM (0.46) SMN1; SMN2NPC1RAB9ATP53CYP1A2
SCHEMBL31661385 0.81 NOTUM (0.45) SMN1; SMN2NPC1RAB9ATP53CYP1A2
SCHEMBL1161278 0.81 MAPT (0.48) SMN1; SMN2NPC1RAB9ATP53CYP1A2
SCHEMBL15972630 0.80 MAPT (0.45) SMN1; SMN2NPC1RAB9ATP53CYP1A2
SCHEMBL30342124 0.80 MAPT (0.45) SMN1; SMN2NPC1RAB9ATP53CYP1A2
SCHEMBL16652958 0.80 GRM4 (0.51) SMN1; SMN2NPC1RAB9ATP53CYP1A2
SCHEMBL23554282 0.79 MAPT (0.55) SMN1; SMN2NPC1RAB9ATP53CYP1A2
SCHEMBL16372000 0.79 LCK (0.47) SMN1; SMN2NPC1RAB9ATP53CYP1A2
SCHEMBL29549633 0.79 MAPT (0.55) SMN1; SMN2NPC1RAB9ATP53CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3156397-B1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICALS CO (JP) 2019-08-07 EP disclosed
US-20170121308-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2017-05-04 US disclosed
EP-3156397-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2017-04-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170121308-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND CHRM1, CHRM5, CHRM2 SMN1; SMN2 515/4885NPC1 777/4885RAB9A 1241/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.